FTC: 12- to 14-year exclusivity for biotech drugs too long

06/10/2009 | Reuters

The 12- to 14-year market exclusivity sought by biotech drugmakers to protect their brand name products is too long because there is a good chance these companies will keep "a substantial market share" when generic counterparts gain FDA approval, according to a Federal Trade Commission report. Copycat biotech drugs, or follow-on biologics, are unlikely to be discounted more than 10% to 30% off the price of brand name medicines, according to the report.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ
RN Care Manager
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC